Pharmaceutical Technology1h
FDA approves Syndax’s Revuforj to treat leukaemia
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.
Pharmaceutical Technology1h
AbbVie’s Elahere wins European approval for certain ovarian cancers
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Pharmaceutical Technology2h
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically ...
Pharmaceutical Technology4h
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
Pharmaceutical Technology3h
AHA 2024: Lerodalciep provides promising results in open-label extension trial, LIBERATE-OLE
At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...